Mangalore API facility margin dilution
Sibaji Biswas explicitly stated all Mangalore costs are routed through P&L with 100-150 bps margin dilution impact. Business development cycles in pharma manufacturing are long.
SYNGENE / Q1-FY24 / risks
Keep the risk register visible.
Syngene International · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Stelis facility revenue timing uncertainty
Analyst pressed on customer pipeline and ramp-up timeline for the Stelis facility. Management deflected by emphasizing strategic rationale (3-year capacity acceleration) rather than revenue visibility. Facility currently has no committed client contracts.
Research services growth normalization
Discovery services growth has returned to more normal levels after unusually high pandemic catch-up demand last year. Private biotech funding environment remains challenging, though management characterizes this as cyclical normalization rather than structural shift.
Hedge losses impacting reported margins
INR 15.5 crore forex loss vs INR 3.4 crore year-ago due to gap between hedge rate (INR 80.3) and spot rate (INR 87.2). This creates margin volatility depending on rupee movement.